Yes, testosterone can increase the risk of blood clots in some men, but the effect is indirect, dose-dependent, and smaller than most headlines suggest. Testosterone stimulates red blood cell production, and in a substantial minority of treated men hematocrit climbs above 52 percent, thickening blood and tilting the coagulation balance. Observational studies link testosterone therapy to roughly a 20 to 60 percent relative increase in venous thromboembolism, while the largest randomized trial found no statistically significant increase in events. So the honest answer sits between: a real, measurable, mechanism-driven risk for susceptible men, not a universal hazard for everyone who takes it.

How Testosterone Raises Clot Risk Through Erythrocytosis

Testosterone does not act on the clotting cascade the way estrogen does. Its main pro-clotting lever is red cell mass. The hormone signals the kidneys to release erythropoietin and suppresses hepcidin, the liver protein that locks iron inside storage cells. With hepcidin suppressed, more iron reaches the marrow, and the marrow builds more red cells.

This is not a subtle effect. In controlled studies, intramuscular testosterone raises hematocrit by roughly 1.5 to 4 percentage points on average, and individual men jump far higher. Some cross the 52 percent mark within months while others barely move.

The hepcidin mechanism is the part most explainers miss. Testosterone suppresses hepcidin in a dose-dependent way, and the effect is stronger with higher circulating levels and with longer-acting formulations. In plain terms: the hormone flips a metabolic switch that keeps iron available for red cell production, even when the body does not need more red cells.

Here is where viscosity enters. Blood viscosity rises exponentially rather than linearly with hematocrit, so the jump from 45 to 52 percent hematocrit matters more than the raw seven points suggest. At very high hematocrit, resistance to flow through small vessels rises sharply, flow slows, and platelets travel closer to the vessel wall. That combination favors thrombus formation, especially in veins.

Testosterone also appears to affect platelet aggregation and some coagulation factor levels, but that evidence is mixed and inconsistent across studies. The red cell pathway is the established one. The FDA added a warning about venous thromboembolism and erythrocytosis to testosterone product labeling in 2015, after a safety review of postmarketing reports.

One more layer: testosterone partly converts to estradiol via aromatase, and estradiol influences clotting factor production. This pathway is real but minor compared with the hematocrit effect, and it is not the main driver of testosterone-associated clots.

Does Testosterone Therapy Increase Blood Clot Risk? The Actual Numbers

The evidence splits by study design, and the split matters.

Observational studies, including large insurance-claims analyses published between 2014 and 2020, report hazard ratios for venous thromboembolism in the range of roughly 1.2 to 1.6 among testosterone users compared with non-users. That translates to a 20 to 60 percent relative increase. Earlier studies with weaker designs produced larger and noisier estimates.

Randomized data tell a calmer story. The TRAVERSE trial, published in 2023, randomized 5,246 men with hypogonadism and cardiovascular risk factors to testosterone gel or placebo. It was designed primarily to test cardiovascular safety, and it found no significant increase in major adverse cardiac events. Venous thromboembolism was not the primary endpoint, so the trial cannot fully rule out a small signal.

A 2024 target-trial emulation published in JAMA Network Open, covering 859,000 men, found the two-year risk of venous thromboembolism was nearly identical between testosterone users and non-users. That result conflicts with the older observational literature, and the likely explanation is confounding. Men who seek testosterone therapy are more often obese, older, and sleep-apneic, and all three independently raise clot risk.

The absolute numbers keep this in perspective. Middle-aged men in the general population experience roughly 1 to 2 venous thromboemboli per 1,000 person-years. A 50 percent relative increase on that base adds about 0.5 to 1 extra event per 1,000 men per year. A 50 percent relative increase sounds alarming, but the baseline is low.

Erythrocytosis is common enough to matter. Depending on formulation and the hematocrit threshold used, roughly 10 to 40 percent of men on testosterone develop hematocrit above 52 percent in published cohorts. Injectable esters cluster at the high end; transdermal gels at the low end.

Injections vs Gels: Which Testosterone Forms Carry Higher Clot Risk

Formulation changes the size of the hematocrit response, and the difference is large enough to guide monitoring.

Formulation Typical dosing interval Erythrocytosis signal in cohorts Practical implication
Transdermal gel or patch Daily Lowest; roughly 5 to 15 percent above 52 percent hematocrit Preferred first choice in men with borderline hematocrit
Intramuscular cypionate or enanthate Every 1 to 2 weeks Moderate to high; peak-and-trough levels drive the marrow hardest Split into weekly or twice-weekly injections to flatten peaks
Subcutaneous auto-injector Weekly Moderate; smoother pharmacokinetics than deep intramuscular Good option when adherence is stable
Oral testosterone undecanoate Twice daily Moderate; data still maturing Requires consistent dosing with food
Subcutaneous pellets Every 3 to 6 months High; sustained supraphysiologic early release Best avoided in men with prior erythrocytosis

The pattern is consistent: the more supraphysiologic the peaks, the bigger the hematocrit rise. Deep intramuscular injections produce sharp peaks that slam the marrow, and later troughs that leave men underdosed. Frequency is a modifiable variable, and splitting the same weekly dose into two injections reduces the peak concentration substantially.

Dose matters independently of formulation. Higher doses produce larger hematocrit increases per unit of time, and there is no evidence that "natural" or compounded products behave differently. The route changes the pharmacokinetics, not the fundamental biology.

Age and baseline fitness alter the response too. Men over 65 and men with obesity, sleep apnea, or smoking histories show larger hematocrit jumps on the same dose. So do men living above 4,000 feet, whose baseline erythropoietin drive is already elevated.

Timeline: When Clot Risk Actually Rises on Testosterone

The risk is not constant across treatment. It concentrates in a predictable window, which is useful for monitoring.

Timepoint What happens Monitoring action
Day 0 Baseline labs drawn before the first dose Hematocrit, testosterone level, blood pressure, sleep apnea screen
Weeks 4 to 8 Erythropoietin rises and reticulocytes increase; hematocrit begins climbing Recheck hematocrit if baseline was above 48 percent
Months 3 to 6 Median hematocrit gain of 1.5 to 4 points; outliers gain 6 to 10 points Mandatory hematocrit check; adjust dose if above 52 percent
Months 6 to 12 Hematocrit plateaus; most erythrocytosis diagnoses appear here Observational studies cluster the clot signal in this first year
Months 12 to 24 Levels stabilize on a steady dose Recheck at least annually, more often if prior elevation
Any time above 54 percent Highest-risk state; viscosity and clot risk both elevated Hold or stop therapy, allow hematocrit to drift down, restart at lower dose
After stopping therapy Red cell mass decays over 3 to 6 months Recheck at 3 and 6 months

The first year carries the loudest signal in the observational data, which fits the physiology. Hematocrit climbs fastest in the first six months, and the men who overshoot are identifiable by month three. After a year on a stable dose, the marrow equilibrates, and the risk curve flattens.

Five Myths About Testosterone and Blood Clots, Corrected

Myth one: testosterone causes clots the way birth control pills do. This is wrong mechanistically. Estrogen-containing contraceptives shift coagulation factors directly and raise venous thromboembolism risk several-fold. Testosterone works through red cell mass, and its measured relative risk is an order of magnitude smaller.

Myth two: only bodybuilders abusing steroids get clots. Prescription-dose replacement has produced erythrocytosis and documented thrombotic events. The risk scales with hematocrit, not with intent, and a man on a standard gel can cross 54 percent.

Myth three: elevated hematocrit always correlates with symptoms. The correlation is weak. Many men at 54 percent feel fine, which is precisely why lab monitoring rather than symptom-based monitoring is the standard of care.

Myth four: erythrocytosis on testosterone is the same as polycythemia vera. These are entirely different conditions. Polycythemia vera is a clonal bone marrow disorder with a much higher intrinsic clot risk. Testosterone-induced erythrocytosis is a reactive, dose-dependent response in